QLT PhotoTherapeutics (QLTI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Doug Lakin who started this subject	2/9/2001 8:57:42 AM
From: sharesighted	of 1321

QLTI;a short perspective;» Figures approx in US dollars PE=230 Revenue/Share=$0.48 EPS was $0.035 which was less than Q3 EPS of $0.04 Analysts' reduced estimates after warning in December that weak demand for its antiblindness drug Visudyne would hurt results. Estimates for Q1 2001 are but $0.046 Projection is company will earn $0.30 for 2001, that would make the PE for todays price 100. Way too high, this stock is going no where for now. Then of course there is the gap to fill which looks to be $25. And the chart indicates there will be resistance at the mid 30's. If you are not short you could try pre-market or when it opens short any rally,there's plenty of shares to borrow. This stock may sink below $25 quite soon. Yes I'm short from yesterday..

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next